Clinical Trials Logo

Lung Cancer Stage III clinical trials

View clinical trials related to Lung Cancer Stage III.

Filter by:

NCT ID: NCT06432972 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Accelerated Pulmonary Rehabilitation in the Preoperative Period

PREHAB
Start date: January 2, 2024
Phase: N/A
Study type: Interventional

This proposed project will be a single arm, non-masked study. Participants who are actively smoking with a diagnosis of COPD and new lung nodule, either confirmed or suspicious for lung cancer, with a plan for surgical resection will be recruited from the University of Vermont Medical Center (UVMMC) Lung Multidisciplinary Clinic (LMDC). All patients will be enrolled in prehab and offered smoking cessation therapy. The acceptability and feasibility of this intervention will be measured by percent enrollment in study, attendance, barriers to completion, and monitoring of adverse events. The effect of prehab will be measured by traditional metrics, including fitness, respiratory symptoms, and depression scale. Research outcomes will be measured by smoking habits, anxiety, and surgical complications. Investigators estimate that 20 participants over a two-year period will be sufficient to measure the safety and feasibility of this study. Investigators aim to enroll, on average, 2 participants per month in order to complete this study in a timely fashion. Participants will be enrolled in prehab on a rolling basis, as to not delay surgical timeline.

NCT ID: NCT06111807 Recruiting - Clinical trials for Lung Cancer Stage III

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC

MRD-LUNG
Start date: November 10, 2023
Phase:
Study type: Observational [Patient Registry]

Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for non small cell lung cancer (NSCLC), the methods used to decide who gets additional post radical (surgery or definite chemo-radiotherapy) treatment are suboptimal. Some patients get too much treatment, while others do not get enough. There is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points. The GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient. GUIDE.MRD-03-NSCLC is a part of the GUIDE.MRD project.

NCT ID: NCT06086574 Recruiting - Clinical trials for Lung Cancer Stage III

Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer

VIGILANCE
Start date: March 24, 2023
Phase:
Study type: Observational

In stage 3 NSCLC, treatment and follow-up are generally performed in a 'one-size-fits-all' manner. In the setting of metastatic lung cancer there has been considerable success identifying biomarkers, which allow treatments to be tailored and lead to more personalised medicine. In patients with stage 3 disease there exists a significant unmet clinical need for equivalent biomarkers to guide treatment decisions such as to identify poor responders, predict benefit from treatment and diagnose relapse before standard of care imaging. Recent advances have made it possible to detect and quantify circulating-tumour DNA in peripheral blood of patients with stage 3 NSCLC, a promising prognostic biomarker and a measure of minimal residual disease. In addition, the information contained in routine medical images and electronic patient reported outcome measure (ePROM) questionnaires can add further predictive power to circulating tumour DNA and other clinical factors to determine patient's outcome. There is scope to integrate biomarkers in treatment decision algorithms aiming to make personalised treatment modifications (e.g. decision to treat with immunotherapy or not). VIGILANCE is a highly exploratory observational study to understand how these biomarkers might inform a future hypothesis driven interventional study.

NCT ID: NCT06060964 Not yet recruiting - Clinical trials for Lung Cancer, Nonsmall Cell

Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management

Breathe Easier
Start date: October 2, 2023
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate the preliminary affects of "Breathe Easier," an evidence-based multi-level mindfulness intervention (i.e., progressive web application) for survivors of lung cancer. The key aims of this study are to (1) Evaluate the feasibility (usability, acceptability intervention adherence) of the "Breathe Easier" and (2) assess the impact of the intervention on dyspnea, fatigue, and quality of life among survivors of lung cancer. Participants in the intervention group will use the "Breathe Easier" progressive web application for a period of 8-weeks, while participants in the control group will receive no intervention. Researchers will compare the intervention and control groups to see if there are salient differences in dyspnea, fatigue, and quality of life between the two groups.

NCT ID: NCT06003075 Recruiting - Clinical trials for Lung Cancer, Nonsmall Cell

Induction Chemo-Nivo in Unresectable Stage III NSCLC

Start date: September 22, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the response rate, safety, and effectiveness of a combination therapy in patients with lung cancer.

NCT ID: NCT05996263 Recruiting - Clinical trials for Lung Cancer Stage IV

Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)

PEMBROMIC
Start date: August 1, 2023
Phase:
Study type: Observational

Pembrolizumab has been approved for first-line locally advanced or metastatic NSCLC with a tumor proportion score (TPS) ≥50% for PDL1, based on the results of KEYNOTE-024. However, even with a positive PDL1 status, only a fraction of patients respond to immunotherapy. In the KEYNOTE-024 study evaluating pembrolizumab versus chemotherapy in first-line advanced NSCLC with PDL1 TPS ≥50%, the response rate in the pembrolizumab arm alone was 45%. NFE2L2 is a transcription factor that directs the expression of free radical defense genes that may interfere with radiation-induced DNA damage. KEAP1 is an adaptor protein that targets NFE2L2 for ubiquitination and proteasomal destruction as part of normal homeostasis. These new biomarkers are of clinical interest, as KEAP1/NFE2L2 mutations predict radiation resistance in patients with localized NSCLC treated with radiotherapy but not surgery. Some data also suggest a role for the KEAP1/NFE2L2 axis in response to immunotherapy. Establishing a predictive model for the presence of the KEAP1/NFE2L2 mutation would provide a tool for predicting survival (progression-free and overall), even before the patient starts immunotherapy.

NCT ID: NCT05994339 Not yet recruiting - Clinical trials for Lung Cancer Stage III

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Start date: September 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Study Object: Stage III lung cancer with epidermal growth factor receptor (EGFR) sensitive mutation. Study Method: The study subjects will be randomly assigned to the intervention group and the control group. The intervention group will receive radiotherapy combined with erlotinib treatment, while the control group will receive concurrent radiotherapy combined with chemotherapy. The differences in short-term efficacy, long-term efficacy, and incidence of adverse reactions between the two groups will be observed. Observation Indicators: Short-term efficacy indicators: Complete remission (CR) rate, partial remission (PR) rate, and objective response rate (ORR). Long-term efficacy indicators: Overall survival (OS) and progression-free survival (PFS). Adverse reaction indicators: Incidence of lung toxicity, hematological toxicity, and gastrointestinal reactions.

NCT ID: NCT05358691 Not yet recruiting - Clinical trials for Lung Cancer Stage III

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Start date: January 30, 2024
Phase: Phase 1
Study type: Interventional

Primary - Evaluate safety and toxicity of AN0025 in both the consolidative setting (after chemoradiation) and in the concurrent setting (during chemoradiation) - Evaluate efficacy by progression-free survival (PFS), objective response rate (ORR), and time to death or distant metastasis (TTMD), Duration of response (DOR), Overall survival (OS) with the addition of AN0025 in both the consolidative and concurrent settings Exploratory - Evaluate pharmacokinetics of AN0025 in conjunction with chemoradiation, and then with durvalumab

NCT ID: NCT05258448 Recruiting - Cardiac Disease Clinical Trials

COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)

COLA
Start date: August 2015
Phase:
Study type: Observational [Patient Registry]

Patients with loco-regional NSCLC planned for curative treatment with chemoradiotherapy will be invited to participate in a prospective study; besides routine treatment, the patients will be followed with an ECG and cardiac MR for at least two years after radiotherapy treatment.

NCT ID: NCT04991025 Recruiting - Lung Cancer Clinical Trials

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Start date: October 19, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the study is to explore adding the study drug certolizumab to standard chemotherapy as it may reduce the inflammation caused by the cancer and make the chemotherapy more effective in shrinking the cancer. This study will examine whether adding certolizumab to the usual treatment approach is better than, the same as, or worse than the usual approach alone.